Stimulated platelets release factor(s) affecting the in vitro response of human polymorphonuclear cells.
The metabolic and functional responses of human polymorphonuclear cells (PMNs) to thrombin-activated platelet supernatants were studied. The incubation of PMNs with supernatants from stimulated platelets (SPS) caused a 50% decrease in both killing of Staphylococcus aureus and luminol-enhanced chemiluminescence (CL) by PMNs stimulated by opsonized-zymosan (OZ), Concanavalin A (Con A), or calcium ionophore A23187. The levels of PMN intracellular fluorescence measured by flow cytometry, using the fluorochrome dichlorofluorescein diacetate (DCF-DA), were considerably less in the presence of SPS than in resting platelet supernatants (RPS). No influence of platelet supernatant on O2 consumption and O2- generation by OZ-activated PMNs was observed. The incubation of PMNs with SPS caused a significant increase in the rate of chemotaxis and aggregation elicited by Con A, OZ, and phorbol myristate acetate (PMA). The supernatant from resting platelets did not show any of the above-reported effects. Platelets previously degranulated by thrombin were unable to inhibit CL when activated with agonists. Studies on the differential release of the granules by platelets showed that the CL-quenching activity paralleled the discharge of lysosomal content. The release of myeloperoxidase (MPO) from PMNs elicited by OZ was reduced in the presence of SPS. The platelet supernatant did not affect the MPO activity if PMNs were lysed with Triton X-100. The leakage of lactate dehydrogenase (LDH) from platelets was less than 3%, and no catalase or superoxide dismutase was released. This activity withstood lyophilization, but was destroyed by 10 min heating at 100 degrees C or by treatment with proteolytic enzymes.
Del Principe
D
D
Department of Public Health and Cellular Biology, University Tor Vergata, Rome, Italy.
Menichelli
A
A
Di Giulio
S
S
De Matteis
W
W
Giordani
M
M
Pentassuglio
A M
AM
Finazzi-Agro
A
A
D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D000001:Calcimycin / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D006801:Humans; D008163:Luminescent Measurements; D008165:Luminol / Q000494:pharmacology; D008247:Lysosomes / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010100:Oxygen / Q000378:metabolism; D015539:Platelet Activation / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
D003208:Concanavalin A; D000001:Calcimycin; D008165:Luminol; D015054:Zymosan; D013917:Thrombin; D013755:Tetradecanoylphorbol Acetate; D010100:Oxygen